M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients

Table 3 The diagnostic criteria of M-CSF and in combination with HE4 and CA 125 in epithelial ovarian cancer patients

Epithelial ovarian cancer	Diagnostic criteria (%)	M-CSF	HE4	CA 125	M-CSF+ HE4	M-CSF + CA 125	HE4+ CA 125	M-CSF + HE4 + CA 125
stage I	SE	40	46	40	64	60	73	80
	SP	94	94	92	90	90	88	86
	PPV	87	88	87	86	86	86	85
	NPV	61	63	61	71	69	76	74
stage II	SE	68	29	63	80	80	81	92
	SP	94	94	92	90	90	88	86
	PPV	92	83	89	89	89	87	87
	NPV	75	57	72	82	82	82	91
stage III	SE	84	66	80	92	94	86	96
	SP	94	94	92	90	90	88	86
	PPV	93	92	91	90	90	86	87
	NPV	85	73	82	92	94	79	94
stage IV	SE	88	81	84	100	96	92	100
	SP	94	94	92	90	90	88	86
	PPV	93	93	91	91	91	88	88
	NPV	87	84	85	100	96	92	100
Total group	SE	70	55	66	84	83	84	86
	SP	94	94	92	90	90	88	86
	PPV	81	90	79	89	89	88	86
	NPV	76	68	73	85	84	86	86
*Serous epithelial*	SE	74	70	64	92	82	86	96
	SP	94	94	92	90	90	88	86
	PPV	92	92	89	90	80	79	87
	NPV	78	77	73	92	83	86	96
*Endometrioid epithelial*	SE	65	37	71	82	89	82	91
	SP	94	94	92	90	90	88	86
	PPV	91	86	90	89	82	87	87
	NPV	73	59	81	83	89	84	92

ISSN: 1757-2215